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Background
Coronavirus disease 2019 (COVID-19) can lead to a
diverse range of clinical manifestations, ranging
from an asymptomatic infection to an acute respira-
tory distress syndrome, and multiorgan failure with
high mortality rates [1]. It is established that SARS-
CoV-2 not only infects the respiratory tract but
that the ensuing viral replication and immune re-
sponse also affects multiple organ systems, in
addition to an acute systemic inflammatory re-
sponse and in some cases accompanying tissue hyp-
oxia and shock.
While many who have been infected have uncom-
plicated recoveries, some have prolonged illness.
Prolonged course of illness has been reported in
adults and children and is affecting both those who
were hospitalised with COVID-19 and those who
were not [2–7].
In December 2020 ISARIC (the International Se-
vere Acute Respiratory and emerging Infection Con-
sortium), the research funders group GloPID-R (The
Global Research Collaboration for Infectious Disease
Preparedness) and global group, Long Covid Sup-
port, jointly organised a ‘Long Covid Forum’ [8].
This public forum aimed to gain a better under-
standing of ‘Long Covid’ and to define research pri-
orities for funders and researchers to take forward.
Emerging themes
Global patient voices
A complex, multi-faceted condition involving a
range of physical, cognitive, psychological and social
implications was described by people living with
Long Covid from around the world. There was a
call for a systematic way to define cases and to
build awareness of Long Covid in the medical com-
munity globally to ensure recognition. Themes of
isolation, social stigma, inability to care for family
and economic repercussions were heard repeatedly.
Integration of multi-disciplinary, holistic care into
health systems is needed, including understanding
the scale of resources that need to be mobilised and
how to ensure equity in access to care across the
world. Specific questions emerged around whether
anti-viral treatment, during acute infection, could
prevent Long Covid and improve long-term out-
comes. Pertinent questions about the need to under-
stand the effect that vaccination may have on
people living with Long Covid were raised.
Overarching summary of knowledge of Long Covid
An analysis by a rapid living systematic review on
Long Covid clinical characteristics [7] highlights the
limited evidence base and heterogeneity in the de-
sign of published studies. Importantly, this work in-
dicates little difference in the severity of symptoms
between the studies in hospitalised and non-
hospitalised groups. An analysis from the UKCDR
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and GloPID-R COVID Research Project Tracker [9]
similarly highlighted little ongoing research on Long
Covid with few studies in non-hospitalised groups
or multi-country studies and no studies in children.
A clear need for further studies in mild infection
cases, including those who did not receive PCR con-
firmation, children and young people, and studies in
different resourced settings using standardised pro-
tocols, risk factors and endpoints was identified to
inform clinical and public health management, re-
habilitation and support.
Country experiences
Research presented from around the world highlighted
heterogeneity in Long Covid presentation, which may be
linked to different treatment responses in the acute
phase of infection. Risk factors—genetic, environmental,
co-morbidities or social—for Long Covid need defining
as well as the impacts of chromic co-infections (e.g. with
HIV and TB) and co-morbidities on disease outcomes.
Reflecting on Chikungunya
There are important similarities between Chikungunya
and COVID-19, including long-lasting and heterogenous
symptoms post-acute infection and research challenges,
due to a lack of standardisation of case definitions, study
measures and inclusion criteria. The importance of in-
vestigating both social and health implications of pro-
longed symptoms was highlighted. There was a
recognition of being prepared to research into the
longer-term effects of any emerging pathogen.
Ongoing Long Covid studies
Emerging results from ongoing research from a range of
countries were presented and discussed to identify mul-
tiple remaining research gaps. These included the need
to understand the mechanism of pathogenesis; the im-
mune response and immune system dynamics (given the
divergent working hypotheses of a failure of adaptive im-
munity to respond enough vs autoimmunity, where a
prolonged or exaggerated response could be damaging);
inclusion of wider populations, including people who
were never hospitalised or even tested; animal and tissue
models; and genetic host factor characterisation. There
is a gap in case-control and interventional studies and
an urgency to understand the aetiology, identify treat-
ments and develop holistic care pathway for rehabilita-
tion, interventions and social support systems.
Psychosocial health
Few studies have focussed on the psychosocial impact of
COVID-19 to date and most lack a comparative group.
Studies indicate that up to a fourth of patients experi-
ence neurological and psychosocial sequelae including
depression and anxiety; the mechanisms underlying
SARS-CoV-2 infection and its effects on the nervous sys-
tem need to be explored to identify the interplay be-
tween neurological symptoms, including those
manifesting as psychological symptoms, the virus and
the immune response. Case-control studies, with
matched control groups within the current pandemic
context, are urgently needed.
Discussion and recommendations
Further action is clearly needed to make sure that Long
Covid does not become the long-lasting legacy of the
pandemic with potentially millions of people suffering,
with an impact on health and social care systems and
wide, long-lasting socioeconomic consequences. Al-
though there is emerging recognition of Long Covid, the
evidence base is limited and fragmented and many re-
search questions remain. The key pressing research
questions are summarised in Table 1 aligned against
WHO priorities [10].
Reorienting and including Long Covid in existing co-
horts, trials and studies might be the most efficient way
to undertake this research globally and strengthen health
systems for future emerging pathogens.
Conclusion
Research on Long Covid will require a multi-disciplinary
and globally coordinated approach that supports harmo-
nised and large-scale case-control and interventional
studies that have the power to provide quality evidence
to inform policy and patient care across the full range of
populations and countries affected.
Governments of the world need to ensure the
strengthening of health systems to be able to provide
treatment, support and rehabilitation to improve long-
term COVID-19 outcomes. To prevent Long Covid be-
coming the pandemic of 2021, controlling the high rates
of infection has to remain a global priority.
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